Future therapeutic interventions aimed at manipulating the ID2-ETS2 axis could potentially alter the dynamics of the tumour microenvironment, providing new avenues for enhancing treatment outcomes in patients with glioblastoma. The gene discussed is ETS2; the disease is glioblastoma.